Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
8.01M
-
Shares change
-
+382K
-
Total reported value, excl. options
-
$103M
-
Value change
-
+$4.47M
-
Number of buys
-
17
-
Number of sells
-
-16
-
Price
-
$12.81
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q1 2017
40 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q1 2017.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.01M shares
of 62.2M outstanding shares and own 12.88% of the company stock.
Largest 10 shareholders include FMR LLC (2.52M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.66M shares), Pharmstandard International S.A. (982K shares), Cormorant Asset Management, LLC (684K shares), RA CAPITAL MANAGEMENT, LLC (636K shares), Foresite Capital Management III, LLC (346K shares), BlackRock Inc. (346K shares), VANGUARD GROUP INC (314K shares), GEODE CAPITAL MANAGEMENT, LLC (101K shares), and STATE STREET CORP (93.1K shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.